Warren Buffett's Successor Greg Abel Dumped 16 Stocks in Q1: Here Are the 2 Biggest Surprises

Berkshire Hathaway under Greg Abel fully exited 16 positions in Q1 2026, including surprising sales of Amazon and UnitedHealth Group, alongside holdings such as Aon, Mastercard, Visa, and Charter. The piece is primarily commentary on portfolio reshuffling and management style rather than a fundamental catalyst, though it argues Amazon and UnitedHealth remain attractive long-term stocks. Market impact is limited because this reflects Berkshire-specific positioning, not new company operating data.

Analysis

The bigger signal is not that Berkshire trimmed a few names, but that the portfolio is being de-complexified into a more controllable, higher-conviction book. That usually benefits the remaining capital allocators: when legacy “process” positions get liquidated, cash and attention migrate toward fewer, larger bets, which can mechanically raise the importance of the next 1-3 incremental purchases. In that sense, the sell list is less about the exiting names and more about the probability of a more concentrated Berkshire deployment cycle over the next 2-4 quarters.

The surprise is the market’s tendency to read these exits as fundamental verdicts. That is especially dangerous for AMZN and UNH, where the timing looks more like governance/ownership housekeeping than a view on terminal value. In both cases the second-order effect is a sentiment reset: any post-sale weakness creates a better entry point for investors with a 12-24 month horizon, because the businesses have clearer operating catalysts than the headline flow implies.

There is also a structural relative-value angle. The financial and payments names on the exit list likely face less incremental “Buffett premium” support, which can matter in periods when passive and quant flows treat Berkshire ownership changes as quality signals. Conversely, AMZN benefits from AI infrastructure optionality and retail/logistics scale, while UNH is set up for mean reversion if medical-cost trends normalize and policy rates stay stable. The near-term risk is that the market over-interprets the sales as a warning and de-rates both stocks for several weeks, but the medium-term catalyst set remains intact unless there is a genuine deterioration in operating data.

Key Decisions for Investors

• Buy AMZN on any 3-5% post-sale drawdown over the next 2-6 weeks; target a 12-18 month upside skew as AI-related capex monetization and satellite optionality re-rate the name.
• Initiate a long UNH position on weakness with a 6-12 month horizon; risk/reward improves if the stock trades at a discount to its historical multiple while medical-cost noise fades.
• Use a pair trade: long AMZN / short a basket of the exited consumer-facing cyclicals (e.g., DPZ, DEO) for 3-6 months; the thesis is that secular winners should outperform names facing slower top-line elasticity and less durable reinvestment runway.
• Fade the knee-jerk selloff in MA/V only if valuation compresses meaningfully; otherwise avoid chasing because the main near-term effect is loss of a signaling holder, not a direct fundamentals downgrade.
• Watch BRK.B for the next 1-2 quarterly filings as a proxy for capital redeployment; if Berkshire becomes a net buyer of a new large position, that is likely a stronger signal than any of the exits in isolation.